On Monday, Pharnext announced the freezing of data from its pivotal Phase III study in Charcot Marie-Tooth disease type 1A, the last step before publication of the clinical trial results.

Verification of the integrity of the clinical data and the official freezing of the database, as of December 1, will now enable the biotech company to lift the blind on the treatment received by patients (PXT3003 or placebo) and initiate the results analysis phase.

Pharnext is therefore maintaining its previously announced timetable, still aiming to release the first data from the Phase III study on December 11, as previously communicated.

Copyright (c) 2023 CercleFinance.com. All rights reserved.